Этиология и возможные механизмы патогенеза апластической анемии

апластическая анемия, стволовая клетка

1. Clausen N., Kreuger A., Salmi T et al. Severe aplastic anaemia in the Nordic countries: a population based study of incidence, presentation, course, and outcome. Arch Dis Child 1996;74:319—22.

2. Issaragrisil S., Kaufman D.W, Anderson T et al. The epidemiology of aplastic anemia in Thailand. Blood 2006;107:1299—307.

3. Kaufman D.W, Kelly J.P., Jurgelon J.M. et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996;60:23—30.

4. Smith M.T Overview of benzene-induced aplastic anaemia. Eur J Haematol Suppl 1996;60:107—10.

5. Cariani E., Pelizzari A.M., Rodella A. et al. Immune-mediated hepatitis-associated aplastic anemia caused by the emergence of a mutant hepatitis B virus undetectable by standard assays. J Hepatol 2007;46:743—7.

6. Hirano N., Butler M.O., Guinan E.C. et al. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol 2005;128:221—3.

7. Hirano N., Butler M.O., Bergwelt-Baildon M.S. et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003;102:4567—75.

8. Feng X., Chuhjo T., Sugimori C. et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004;104:2425—31.

9. Takamatsu H., Feng X., Chuhjo T et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood 2007;109:2514-20.

10. Sugimori C., Yamazaki H., Feng X. et al. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol 2007;35:13-20.

11. Fuhrer M., Durner J., Brunnler G. et al. HLA association is different in children and adults with severe acquired aplastic anemia. Pediatr Blood Cancer 2007;48:186-91.

12. Risitano A.M., Maciejewski J.P., Green S. et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004;364:355-64.

13. Piao W, Grosse J., Czwalinna A. et al. Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. Exp Hematol 2005;33:804-10.

14. Young N.S. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2000;37:3-14.

15. LiW, Fu J., Wang, F. et al. Distinct overexpression of Fas ligand on T lymphocytes in aplastic anemia. Cell Mol Immunol 2004;1:142-7.

16. Dubey S., Shukla P., Nityanand S. Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. Ann Hematol 2005;84:572-7.

17. Verma A., Deb D.K., Sassano A. et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002;168:5984-8.

18. Giannakoulas N.C., Karakantza M., Theodorou G.L. et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol 2004;124:97-105.

19. ZengW, Kajigaya S., Chen G. et al. Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol 2004;32:806-14.

20. Gidvani V., Ramkissoon S., Sloand E.M., Young N.S. Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol 2007;82(8):721-4.

21. Solomou E.E., Keyvanfar K., Young N.S. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006;107:3983-91.

22. Solomou E.E., Gibellini F., Stewart B. et al. Perforin gene mutations in patients with acquired aplastic anemia. Blood 2007;109(12):5234-7.

23. Solomou E.E., Visconte V., Gibellini F., Young N.S. SAP (SH2D1A), the Immunomodulator Deficient in X-Linked Lymphoproliferative Syndrome (XLP), Is Profoundly Decreased in Aplastic Anemia: An Immunologic Link between Constitutional and Acquired Bone Marrow Failure. Blood 2006;108:1141.

24. Solomou E.E., Rezvani K., Mielke K. et al. FOXP3-positive regulatory T-cells in acquired aplastic anemia. Blood 2006;108:2248.

25. HinterbergerW, Rowlings PA., Hinterberger-Fischer M. et al. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med 1997;126:116-22.

26. Marsh J.C., Chang J., Testa N.G. et al. In vitro assessment of marrow 'stem cell' and stromal cell function in aplastic anaemia. Br J Haematol 1991;78:258-67.

27. Zeng W, Chen G., Kajigaya S. et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood 2004;103:325-32.

28. Calado R.T., Garcia A.B., Gallo D.A., Falcao R.P Reduced function of the multidrug resistance P-glycoprotein in CD34+ cells of patients with aplastic anaemia. Br J Haematol 2002;118:320-6.

29. Yamaguchi H., Calado R.T., Ly H. et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413-24.

30. Yamaguchi H., Baerlocher G.M., Lansdorp P.M. et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003;102:916-8.

31. Hotta T., Kato T., Maeda H. et al. Functional changes in marrow stromal cells in aplastic anaemia. Acta Haematol 1985;74:65-9.

32. Bacigalupo A., Valle M., Podesta M. et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005;33:819-27.

33. Taichman R.S. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005;105:2631-9.

34. Calvi L.M., Adams G.B., Weibrecht K.W et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841-6.

35. Yin T, Li L. The stem cell niches in bone. J Clin Invest 2006;116:1195-201.

36. Ng Y.S., Krilleke D., Shima D.T VEGF function in vascular pathogenesis. Exp Cell Res 2006;312:527-37.

37. Petrova N.Y, Svinareva D.A., Nifontova I.N. et al. Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone. Bull Exp Biol Med 2006;142:527-30.

38. Sugimori C., Chuhjo T, Feng X. et al. Minor population of CD55-. Blood 2006;107:1308-14.

39. Mochizuki K., Sugimori S., Feng X. et al. Small populations of PNH-type cells in aplastic anemia patients are derived from PIG-A mutant stem cell clones without proliferative advantage. Blood 2006;108:974.

40. Chen G., Zeng W, Maciejewski J.P et al. Differential gene expression in hematopoietic progenitors from paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in 'normal' phenotype cells. Leukemia 2005;19:862-8.

41. Marsh J. Making therapeutic decisions in adults with aplastic anemia. Hematology Am Soc Hematol Educ Program 2006;78-85.

42. Marsh J.C., Ball S.E., Darbyshire P et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003;123:782-801.

43. Locasciulli A., Oneto R., Bacigalupo A. et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007;92:11-8.

44. Frickhofen N., Heimpel H., Kaltwasser J.P, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.

45. Bacigalupo A., Bruno B., Saracco P et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931-4.

46. Marsh J.C. Treatment of acquired aplastic anemia. Haematologica 2007;92:2-5.

47. Champlin R.E., Perez WS., Passweg J.R. et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007;109(10):4582-5.

48. Kobayashi R., Yabe H., Hara J. et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identi-cal siblings. Br J Haematol 2006;135:693-6.

49. Goerner M., Gooley T, Flowers M.E. et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002;8:47-56.

50. Ohga S., Ichino K., Goto K. et al. Unrelated donor cord blood transplantation for childhood severe aplastic anemia after a modified conditioning. Pediatr Transplant 2006;10:497-500.

51. Miyazaki Y, Nakamichi N., Matsumoto N. et al. [Unrelated HLA-mismatched cord blood transplantation using nonmyeloablative conditioning in an adult patient with very severe aplastic anemia. Rinsho Ketsueki 2003;44:965-7.

52. Mao P, Zhu Z., Wang H. et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol 2005;75:430-5.

53. Kook H., Baek H.-J., Hwang, T.-J. et al. Unrelated donor umbilical cord blood transplantation in children with acquired aplastic anemia. Korean Experience of 12 Cases. Blood 2006;108:5402.

54. Mikhailova E.A., Savchenko V.G., Ustinova E.N. et al. [Splenectomy in programmed therapy of aplastic anemia]. Ter Arkh 2006;78:52-7.